Inhoudsopgave:
|
\u003cb\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c/b\u003e \u003cp\u003e\u003cb\u003eA comprehensive review of the latest molecular advances in cancer treatment\u003c/b\u003e \u003cp\u003eFeaturing 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c/i\u003e documents the recent scientific advances that have transformed one of medicine\u0026#8217;s most challenging areas\u0026#8212;cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented. \u003cp\u003eWith a very well-known chemist as an author, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c/i\u003e includes information on: \u003cul\u003e\u003cli\u003eEach molecule\u0026#8217;s structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action\u003c/li\u003e \u003cli\u003eMutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent\u003c/li\u003e \u003cli\u003eHistory of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer\u003c/li\u003e \u003cli\u003eThe discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field\u003c/li\u003e\u003c/ul\u003e \u003cp\u003eCombining the most significant recent discoveries in a unique and useful way, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c/i\u003e is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology as well as for those at industrial companies involved in therapeutic discovery. |
nl
en